Oral SERDs after SERENA-4: narrower bets, not the end of the class

The immediate takeaway is that SERENA-4 is a setback for using an oral SERD routinely from the start of treatment—not a verdict on the whole class. AstraZeneca said camizestrant (Etcamah) plus palbociclib did not significantly improve progression-free survival over anastrozole plus palbociclib in first-line advanced ER-positive, HER2-negative breast cancer, despite a numerical improvement. Detailed results have not yet been reported in the sources available here.

The failure reinforces a tough first-line pattern:
Roche’s oral SERD giredestrant also missed its first-line phase 3 trial. That raises the bar for other broad first-line programs, including Olema’s palazestrant plus palbociclib, but does not establish that they will fail.

Camizestrant’s more focused ESR1-mutation strategy remains distinct. The available reports say it is approved in several markets for advanced HR-positive, HER2-negative disease when an ESR1 mutation emerges during first-line endocrine-based therapy, based on SERENA-6. SERENA-4 does not, by itself, undo that indication.

So the likely direction is more targeted use and sharper trial design:
identify patients whose tumors acquire ESR1 mutations, and establish the benefit of switching treatment at that point. The unresolved issues include how meaningful the benefit is in routine practice and how best to monitor patients.

The longer-term class opportunity may be earlier-stage disease. AstraZeneca is continuing CAMBRIA-1 and CAMBRIA-2; reports expect a CAMBRIA-1 readout in 2027, while CAMBRIA-2 is further out. Those trials could matter more to the class’s future than another unselected first-line metastatic trial.